# AI Assisted Mechanistic and Translational Evaluation of Moringa oleifera in Alzheimer's disease: A Preclinical-to-Clinical Study

**Siddik Anwar Bagwan [1], Dr Pravin Badhe[2]**

[1]Department of Pharmacy, Sinhgad College of Pharmacy, Savitribai Phule Pune University, Pune

[2]Swalife Biotech Pvt Ltd., Pune, Maharashtra, India

**Corresponding author Email:** bagwansiddik50@gmail.com
**Doi: https://doi.org/10.5281/zenodo.20179920**
**Received:** 19 April 2026
**Accepted:** 26 April 2026

**Abstract**

Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder characterized by amyloid-β deposition, tau pathology, oxidative stress, and chronic neuroinflammation. Current therapeutic options provide only symptomatic relief, underscoring the need for novel, multi-target strategies. This study investigates the potential of Moringa oleifera as a phytotherapeutic candidate for AD by systematically reviewing preclinical and translational evidence. The plant is rich in bioactive compounds, particularly flavonoids such as quercetin and kaempferol, which demonstrate antioxidant, anti-inflammatory, and cholinesterase inhibitory properties. Computational analyses, including molecular docking and pharmacokinetic predictions, suggest favorable drug-like characteristics and interactions with key AD-related pathways, including NF-κB, Nrf2, and amyloidogenic mechanisms. Experimental studies in vitro and in vivo consistently report neuroprotective effects, including reduced oxidative stress, decreased amyloid burden, improved cognitive performance, and modulation of inflammatory mediators. Despite these promising findings, clinical validation remains limited, with challenges related to standardized formulations and the absence of large-scale human trials. Overall, Moringa oleifera emerges as a promising adjunct candidate for AD management, warranting further translational and clinical investigations to establish its therapeutic efficacy and safety in humans.

Keywords

Alzheimer's disease; Moringa oleifera, NF-κB, Nrf2, amyloid, large language models; AI-driven drug discovery; network pharmacology; Neurodegeneration

## 1. Introduction

### 1.1Artificial Intelligence (AI)

Artificial Intelligence (AI) is a branch of computer science that focuses on creating systems capable of performing tasks that usually require human intelligence, such as learning, reasoning, and decision-making. AI operates through algorithms that process data and generate outputs. A major subset, Machine Learning (ML), enables systems to learn from data and improve performance over time without explicit programming. Deep Learning (DL), a more advanced form, uses multi-layered neural networks to analyse complex datasets such as images and molecular structures. In pharmaceutics, AI includes tools like neural networks, generative models, and natural language processing to analyze biological and chemical data and support drug development decisions[1].The integration of AI in drug discovery and development has significantly improved efficiency by reducing time, cost, and failure rates. Traditionally, drug development takes 10–17 years with high costs and low success rates. AI accelerates early drug discovery by identifying disease targets and enabling virtual screening of large chemical

libraries to predict interactions between drugs and target proteins. It also supports de novo drug design by generating new molecular structures and predicts protein structures, aiding structure-based drug design. Additionally, AI helps in early prediction of ADMET properties, reducing the risk of failure in later stages.[2] AI also enhances clinical trials by improving patient recruitment through analysis of electronic health records and optimizing trial design with real-time monitoring. It plays a key role in personalized medicine by predicting individual responses based on genetic and environmental factors.[3] Furthermore, AI improves pharmaceutical manufacturing through automation, quality control, and supply chain optimization.




**Figure 1**: Recent Advancements in AI-Driven Drug Discovery: A Comparative Trend (2015–2025)

Despite challenges such as data quality, ethical concerns, and regulatory limitations, AI continues to show great potential in transforming drug development and delivering safer and more effective therapies.[4]

### 1.2 Scientific Prompting in Drug Discovery

Scientific prompting is an emerging approach in pharmaceutical research that involves carefully designing inputs to guide advanced computational models in generating accurate and context-relevant scientific outputs. Unlike traditional machine learning models that are trained for specific predictive tasks, this approach allows researchers to interact with systems more flexibly to extract insights, generate hypotheses, and support experimental planning. It enables efficient analysis of large volumes of scientific literature, helping identify relationships between genes, diseases, and drug candidates.[5] This approach also supports hypothesis generation by suggesting potential drug–target interactions or repurposing opportunities based on existing data. In addition, it facilitates automation by assisting in the generation of computational workflows, data analysis scripts, and structured outputs such as molecular representations, which can be directly used in drug design pipelines. Furthermore, it can aid in drafting research protocols and summarizing experimental findings, thereby improving efficiency in documentation and reporting.[6]

AI-assisted drug discovery and development integrate these advanced computational approaches to enhance various stages of the pharmaceutical pipeline. It accelerates target identification by analyzing biological datasets and supports virtual screening to evaluate interactions between compounds and biological targets. It also enables the design of novel molecules with desired properties and predicts pharmacokinetic and toxicity profiles at early stages, reducing the likelihood of failure in later phases. In clinical development, it improves patient selection, trial design, and real-time monitoring, leading to more efficient and adaptive studies. Additionally, it contributes to personalized medicine by predicting individual responses based on genetic and environmental factors. Overall, these advancements improve the speed, accuracy, and cost-effectiveness of drug development while supporting more informed and data-driven decision-making in pharmaceutics.[7]

### 1.3 AI-Assisted Drug Discovery and Development

AI-assisted drug discovery and development have evolved into a highly integrated process in which traditional computational methods such as machine learning, deep learning, and reinforcement learning are combined with advanced interactive approaches to enhance efficiency and decision-making. This integration creates a collaborative framework where computational systems support researchers across multiple stages of the pharmaceutical pipeline. In target identification, advanced algorithms analyze multi-omics data and biological networks to predict disease-relevant targets, while interactive querying of scientific literature and databases helps validate their relevance and novelty. During hit identification, computational models perform large-scale virtual screening and generate novel molecular structures, whereas guided inputs allow researchers to define chemical constraints and explore chemical space more intuitively. In lead optimization, predictive models evaluate pharmacokinetic and toxicity profiles, while iterative refinement supports structural modifications and interpretation of potential safety concerns.[8]

In clinical trial design, computational tools assist in patient stratification and site selection using real-world data, while automated systems help draft eligibility criteria and streamline communication processes. Similarly, in regulatory and documentation processes, computational models standardize data and predict submission outcomes, while automated drafting tools assist in preparing technical documents and responding to regulatory queries. A notable example of such integration is the use of advanced protein structure prediction systems alongside interactive computational models, enabling researchers to identify binding sites, propose candidate molecules, evaluate their feasibility, and outline synthesis protocols within a unified workflow.[9,10]

Despite these advancements, several challenges remain. The reliability of generated outputs must be carefully validated, as inaccuracies can occur. Domain-specific training using high-quality chemical and biological datasets is essential to improve performance. Effective integration with established cheminformatics tools ensures scientific validity, while maintaining reproducibility and transparency requires proper documentation of computational workflows and input strategies. Overall, this integrated approach significantly enhances the speed, precision, and adaptability of drug discovery and development processes.[6,11]

**Table1**.Integration of AI/ML and Scientific Prompting Across Drug Discovery and Development Stages

| Stage | AI/ML Role | Role of Scientific Prompting |
|---|---|---|
| **Target Identification** | Multi-omics data integration and network analysis to predict disease-relevant targets | Querying scientific literature and knowledge graphs to validate target novelty and disease association |
| **Hit Identification** | Virtual screening of large compound libraries; generative models (GANs, VAEs) for de novo drug design | Specification of chemical constraints using natural language; interactive exploration of chemical space |
| **Lead Optimization** | Prediction of ADMET properties; multi-parameter optimization for efficacy and safety | Iterative refinement of molecular structures; explanation and interpretation of predicted toxicity |
| **Clinical Trial Design** | Patient stratification and site selection using real-world data and ML models | Drafting inclusion/exclusion criteria; automating patient recruitment communication |
| **Regulatory & Documentation** | Data standardization; predictive modeling for regulatory submission outcomes | Drafting CTD modules; responding to regulatory queries with evidence-based outputs |

### 1.4 Swalife Prompt Studio as a Tool for Scientific Prompt Engineering

Swalife Prompt Studio is an advanced AI-driven scientific prompting platform developed by Swalife Biotech under MolecuNex AI. It is designed to enhance the quality, clarity, and structure of interactions with large language models in pharmaceutical and biomedical research. Rather than generating direct answers, the platform creates highly structured, domain-specific prompts, enabling researchers, pharmacovigilance professionals, and regulatory teams to formulate precise and scientifically relevant queries. By defining key parameters such as

disease or indication, drug category, and herbal or nutraceutical product, users can obtain expert-level prompts aligned with global pharmacovigilance requirements.

The platform follows a workflow-based modular architecture that reflects the complete pharmacovigilance lifecycle, including adverse event collection, data coding, signal detection, causality assessment, and regulatory reporting. This structured approach ensures that AI-generated outputs remain consistent, traceable, and compliant with international standards such as ICH and WHO guidelines. Importantly, Swalife Prompt Studio functions as a supportive guidance system rather than a replacement for human expertise, improving the accuracy, reproducibility, and reliability of AI-assisted research. By embedding scientific reasoning into prompt generation, it minimizes errors, enhances data interpretation, and supports applications in drug discovery, safety monitoring, and integrative medicine, particularly in the study of herbal drug interactions. Overall, it represents a transition from using AI as a simple text-generation tool to leveraging it as a structured system for scientific reasoning driven by high-quality prompts.




**Figure 2**.AI-Driven Prompt Generation Platform (Swalife Prompt Studio)

### 1.5 Alzheimer's Disease: Pathophysiology, Current Therapeutics

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide, characterized by memory loss, cognitive decline, and behavioral disturbances. It accounts for approximately 60-80% of dementia cases and primarily affects the elderly population. The disease is irreversible and progressively impairs daily functioning, creating a significant global health burden. The hallmark pathological features of AD include extracellular amyloid-β (Aβ) plaques, intracellular neurofibrillary tangles, and neuronal loss. Despite extensive research, current treatment strategies provide only symptomatic relief and fail to stop disease progression, highlighting the urgent need for effective therapeutic interventions.[12]

The pathophysiology of Alzheimer's disease is complex and multifactorial. The amyloid cascade hypothesis suggests that abnormal accumulation of Aβ peptides leads to plaque formation, which disrupts neuronal communication and induces neurotoxicity. [12]Another key feature is tau protein hyperphosphorylation, resulting in neurofibrillary tangles that destabilize microtubules and contribute to neuronal degeneration. In addition, neuroinflammation and oxidative stress play significant roles in disease progression, as chronic activation of microglial cells leads to sustained inflammation and increased production of reactive oxygen species. Neurotransmitter deficiency, particularly reduced levels of acetylcholine, further contributes to cognitive impairment and forms the basis for current pharmacological therapies. Moreover, genetic, environmental, and metabolic factors such as mitochondrial dysfunction, metal imbalance, and vascular abnormalities also influence disease development.[13]

Clinically, Alzheimer's disease progresses through early, moderate, and severe stages. The early stage is characterized by mild memory loss and confusion, while the moderate stage involves worsening cognitive decline, behavioral changes, and difficulty recognizing familiar individuals. In the severe stage, patients experience loss

of communication abilities and become completely dependent on caregivers. Diagnosis is primarily based on clinical evaluation, cognitive tests, neuroimaging techniques such as MRI and PET scans, and biomarker analysis of amyloid and tau proteins, with recent advancements focusing on early detection[14].

Pharmacological management of AD includes cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine, which enhance acetylcholine levels and improve cognitive symptoms, and memantine, an NMDA receptor antagonist that reduces glutamate-induced excitotoxicity. However, these drugs do not alter disease progression. Therefore, emerging therapeutic strategies are being explored. Disease-modifying therapies, including monoclonal antibodies targeting amyloid plaques, have shown limited success. [13,15]Combination therapies targeting multiple pathological pathways simultaneously are gaining attention as a more effective approach. Additionally, artificial intelligence is increasingly used in Alzheimer's research for early diagnosis and drug discovery. Herbal and natural compounds with antioxidant and anti-inflammatory properties are also being investigated due to their multi-target potential and better safety profiles.[12]

### 1.6 Moringa oleifera as a Multi-Target Neuroprotective Agent

Moringa oleifera has emerged as a promising multi-target agent in the management of Alzheimer's disease (AD), a progressive neurodegenerative disorder characterized by cognitive decline, amyloid-β (Aβ) plaque deposition, neurofibrillary tangles, and neuronal loss. The therapeutic potential of Moringa oleifera is primarily attributed to its rich phytochemical profile, including flavonoids (quercetin, kaempferol), phenolic acids (chlorogenic acid), glucosinolates, and vitamins, which collectively exert neuroprotective effects.[16] One of the major mechanisms involves its potent antioxidant activity, which reduces oxidative stress a key contributor to neuronal degeneration in AD by scavenging reactive oxygen species and enhancing endogenous antioxidant defenses. [16]Additionally, Moringa exhibits anti-amyloidogenic properties by inhibiting the aggregation and deposition of Aβ peptides, thereby reducing plaque formation and associated neurotoxicity. It also demonstrates significant anti-cholinesterase activity by inhibiting acetylcholinesterase (AChE), leading to increased acetylcholine levels in the brain and improved cognitive function, similar to currently used symptomatic treatments. [17]Furthermore, its anti-inflammatory effects help mitigate neuroinflammation by modulating pro-inflammatory cytokines such as IL-1β and TNF-α, which are known to accelerate AD progression. [18]Emerging evidence also suggests that Moringa may influence tau pathology by regulating kinases like glycogen synthase kinase-3β (GSK-3β), thereby reducing tau hyperphosphorylation and neurofibrillary tangle formation.[17]

In recent years, artificial intelligence (AI)-assisted drug discovery has significantly enhanced the exploration of natural products like Moringa oleifera for AD therapy. AI-driven approaches such as molecular docking, virtual screening, and machine learning-based predictive models enable rapid identification of bioactive compounds and their potential targets. Phytoconstituents of Moringa, including quercetin and glucomoringin, have been evaluated using in silico techniques against key AD targets such as acetylcholinesterase, β-secretase (BACE1), and amyloid precursor protein, demonstrating strong binding affinities and therapeutic potential. Additionally, ADMET (absorption, distribution, metabolism, excretion, and toxicity) prediction tools like SwissADME and pkCSM help assess drug-likeness and safety profiles early in the drug development process, thereby reducing time and cost. Molecular dynamics simulations further validate the stability and interaction of ligand target complexes, providing insights into their efficacy under physiological conditions. Network pharmacology, another AI-enabled approach, is particularly valuable for herbal drugs as it integrates multi-target and multi-pathway interactions, aligning with the holistic nature of phytotherapy. This approach helps elucidate how Moringa compounds simultaneously modulate oxidative stress, inflammation, amyloidogenesis, and neurotransmitter imbalance in AD.[19,20]

## 2 Material and methodology

### 2.1 LLM in AI assisted drug discovery and development

Large language models are becoming important tools in drug discovery and development. They can quickly analyse huge amounts of scientific data, helping researchers identify new disease targets and uncover patterns that would take much longer to find manually. They are also capable of designing new molecules from scratch, giving scientists more options beyond existing compound libraries.[21]

These models are also improving how drug safety and effectiveness are predicted. By analyzing biological and chemical data, they can estimate how a drug will behave in the body, reducing the chances of failure in later stages. This helps save time, cost, and resources.[22]

In clinical trials, LLMs are making processes faster and more efficient. They assist in designing trials, selecting suitable patients, and analysing medical records. Regulators are also beginning to use similar tools to review data more quickly. In some cases, virtual patient models are used to simulate outcomes and reduce the need for large control groups.[23]




**Figure A:** LLM Applications in Drug Discovery
**Figure B:** Comparison of Traditional vs LLM-based Drug Discovery
**Figure C:** Working Mechanism of a Large Language Model

**Figure 3.** Figure: Integrated Overview of Large Language Models (LLMs) in Drug Discovery—Applications, Comparative Performance, and Working Mechanism

### 2.2Perplexity in AI assisted drug discovery and development

Perplexity is an AI-powered search and answer engine that combines real-time web browsing with advanced large language models to deliver fast, accurate, and well-cited responses. It works by first understanding the user's query and intent, then searching the live web, analyzing multiple reliable sources, and synthesizing the information into a clear, conversational answer with inline citations that link back to original content.[24] Unlike traditional search engines that mainly provide lists of links, or standalone chatbots that may lack source transparency, Perplexity sits in between as an answer engine, offering structured responses backed by verifiable references. It includes multiple modes such as regular Search for quick results, Pro Search for more detailed multi-source answers, and Deep Research for comprehensive, report-style outputs that involve iterative reasoning and extensive document analysis. Advanced features like Labs or "Create files and apps" further enable users to generate reports, dashboards, spreadsheets, and even simple applications using natural language prompts. [24]The platform integrates powerful AI models, including versions of OpenAI's GPT and Anthropic's Claude, and offers both free and paid plans, with premium tiers providing enhanced capabilities, higher usage limits, and access to advanced tools. [25]With a strong focus on transparency, citation accuracy, and multi-source synthesis, Perplexity is especially valuable for academic, technical, and professional research, as well as enterprise use cases where both internal and external data can be analyzed to automate research workflows and produce high-quality, evidence-based outputs.[24]

### 2.3 Module 1: Target and Mechanism




**Figure 4:** Target and Mechanism Prompt Interface of Swalife MolecuNex AI for Alzheimer's Disease moringa Analysis.

The first step of the AI-assisted research workflow to methodically assess the mechanistic significance of Moringa oleifera bioactive chemicals in alzhemier pathways was the Target and Mechanism module.The Perplexity Pro Sonar model was used to process all of the structured prompts used in this module's execution within the SwaLife AI Discovery & Study Design Studio workflow. Pathway mapping and public-domain database mining were the main topics of Section 1 (Prompts 1–20). Molecular targets, signaling pathways, and protein–protein interaction networks linked to Moringa oleifera this study were designed using an integrated AI-assisted computational framework combining network pharmacology, cheminformatics, and predictive modeling approaches to evaluate the drug delivery potential of Moringa oleifera bioactives in Alzheimer's disease (AD). Phytochemical constituents including glucomoringin, moringin, quercetin, and kaempferol were collected from published literature, curated databases, and previously reported datasets, while AD-associated targets and pathways were retrieved from databases such as PubMed, DisGeNET, and KEGG. Key biological pathways involved in disease progression, including NF-κB signaling, Nrf2-mediated antioxidant response, amyloid-beta processing, and neuroinflammatory pathways, were identified and selected for further analysis. All phytoconstituents were standardized using molecular descriptors such as SMILES and InChI formats to ensure compatibility with computational tools.

Artificial intelligence-based models and machine learning algorithms were employed to predict compound–target interactions, binding affinities, and multi-target pharmacological profiles. Network pharmacology analysis was conducted to identify overlapping and functionally relevant targets, including AKT1, STAT3, TNF-α, and IL-6, which were prioritized based on their roles in oxidative stress and neuroinflammation. Molecular docking studies were performed using protein structures obtained from the Protein Data Bank (PDB), followed by ligand preparation, energy minimization, and docking using AI-enhanced scoring functions to evaluate binding interactions with AD-relevant targets.

Methodology planning, validation techniques, and hypothesis formulation were the main topics of Section 2 (Prompts 21-40). The prompts produced suggestions for experimental design, such as multi-marker validation panels To facilitate mechanistic interpretation and translational planning, the AI-generated outputs were organized into bullet-based interpretations, route frequency tables, and disease–plant relationship summarie Standard operating procedure (SOP) planning for in vitro validation studies, experimental schedules, and biomarker bridging techniques were among the translational planning components included in the module. The establishment of target validation strategies and early translational research planning for Moringa oleifera in Alzheimer research were facilitated by this procedure.

### 2.4 Module 2: Lead Id and Optimization




**Figure 5:** Lead Identification and Optimization Prompt Interface of Swalife MolecuNex AI for Alzheimer's Disease moringa Analysis

this study was developed using an AI-assisted lead identification and optimization workflow to evaluate Moringa oleifera bioactive compounds for Alzheimer's disease. The Lead Identification and Optimization module was implemented as a structured computational phase, wherein standardized scientific prompts were generated using the SwaLife AI Discovery & Study Design Studio and processed through advanced large language models for systematic data extraction, interpretation, and hypothesis generation. The methodology was divided into two sequential sections comprising 40 prompts designed to ensure comprehensive coverage of phytochemical profiling, drug-likeness screening, and lead optimization strategies.

In the initial phase (Section 1: Prompts 1–20), data collection and curation were performed by extracting publicly available information related to Moringa oleifera phytoconstituents, including flavonoids (quercetin, kaempferol), phenolic acids, glucosinolates, and alkaloids. Compounds were classified into chemical groups and evaluated for their pharmacological relevance using literature databases and curated datasets. Drug-likeness assessment and ADMET profiling were conducted using computational tools such as SwissADME and related predictive platforms to evaluate parameters including molecular weight, lipophilicity, hydrogen bonding, gastrointestinal absorption, and toxicity. Additionally, prompts were designed to retrieve previously reported in vitro and in silico studies targeting Alzheimer's-related enzymes such as acetylcholinesterase, butyrylcholinesterase, and amyloid-beta pathways. Bioactivity-guided fractionation data were also incorporated to identify active fractions enriched with polyphenols and flavonoids, particularly from leaf extracts.

In the second phase (Section 2: Prompts 21–40), emphasis was placed on lead optimization, mechanistic insights, and experimental design. Structure–activity relationship (SAR) analysis was performed to understand the correlation between chemical structure and biological activity, followed by AI-assisted prediction of potential chemical modifications to enhance bioavailability, target specificity, and pharmacokinetic properties. Molecular docking simulations and binding affinity predictions were conducted using tools such as AutoDock to evaluate interactions between selected phytochemicals and Alzheimer's disease targets. Network pharmacology approaches were integrated to map compound–target–pathway interactions and identify key biological nodes involved in neurodegeneration.

Further, AI-based models were employed to predict blood–brain barrier permeability, toxicity profiles, and multi-parameter optimization criteria including potency, selectivity, and safety. The methodology also incorporated the design of suitable in vitro validation strategies, including neuronal cell line assays and enzyme inhibition studies, to support future experimental translation. Formulation-oriented prompts were included to explore advanced drug delivery approaches such as nanoemulsions, self-nano-emulsifying systems, and lipid-based carriers to improve the stability and bioavailability of selected leads.

All outputs generated through this workflow were systematically organized into structured compound profiles, classification summaries, and interpretation-based datasets to facilitate lead prioritization. The entire

computational process was supported by Python-based AI/ML frameworks, Cytoscape for network analysis, and STRING database for protein–protein interaction studies, ensuring a reproducible and integrative methodology for AI-assisted drug discovery and delivery optimization.

### 2.5 Module 3: In Vitro Design




**Figure 6**: In Vitro Design Prompt Interface of Swalife MolecuNex AI for Alzheimer's Disease moringa Analysis.

this study was designed using an AI-assisted in-vitro experimental workflow to evaluate the neuroprotective potential of Moringa oleifera in Alzheimer's disease models. The In-Vitro Design module was implemented as part of the structured AI research pipeline, where standardized prompts were generated using the SwaLife AI Discovery & Study Design Studio and processed through advanced language models for systematic experimental planning and data extraction. Section 1 (Prompts 1–20) focused on identifying suitable in-vitro models, including 2D monocultures, co-culture systems, and advanced 3D models, along with selection of appropriate assays for cytotoxicity, oxidative stress, and neuroprotection. Data related to phytochemical activity, assay compatibility, and previously reported Alzheimer's studies were collected from literature sources and curated datasets.

Section 1 also included evaluation of drug-likeness in experimental conditions, assay selection such as MTT, LDH, ROS, and antioxidant enzyme analysis (SOD, CAT, GSH-Px), and identification of key mechanistic biomarkers including caspase-3, Bcl-2, IL-6, TNF-α, and COX-2. Standard experimental parameters such as extract concentration (10–100 µg/mL), solvent systems (aqueous, ethanol, methanol), incubation time (24–48 hours), and cell culture conditions (pH 7.4, 37°C) were defined. Prompts were also used to extract information on assay interference, reporting standards, and quality control measures to ensure reproducibility and accuracy in plant-based in-vitro studies.

Section 2 (Prompts 21–40) focused on experimental design, lead validation, and optimization strategies. This included development of dose-response studies, pre-treatment and co-treatment experimental models, and combination studies with standard drugs such as donepezil. AI-assisted prompts were used to design structured in-vitro experiments using SH-SY5Y cells exposed to amyloid-beta (Aβ1-42), with endpoints including cell viability and oxidative stress. The workflow also incorporated statistical analysis (mean ± SEM, ANOVA), use of biological replicates (n=3), and structured data recording using electronic lab notebook templates. This integrated approach enabled systematic evaluation, validation, and optimization of Moringa oleifera as a potential multi-target therapeutic candidate for Alzheimer's disease.

### 2.6 Module 4: In Vivo Design




**Figure 7**: in vivo design Prompt Interface of Swalife MolecuNex AI for Alzheimer's Disease moringa Analysis

AI-assisted in vivo experimental design framework to evaluate the neuroprotective potential of Moringa oleifera in Alzheimer's disease. The In Vivo Design module was implemented as a structured component of the AI-driven workflow, where standardized prompts were generated using the SwaLife AI Discovery & Study Design Studio and processed through advanced computational models for systematic experimental planning, model selection, and protocol development. Section 1 (Prompts 1–20) focused on the extraction and interpretation of public-domain data related to animal models, induction methods, dosing strategies, and safety profiles. Various Alzheimer's disease models, including induced (scopolamine, streptozotocin, aluminum chloride) and transgenic models (APP/PS1, 3xTg-AD), were identified and evaluated for their relevance to disease pathology and phytochemical testing.

This phase also included the identification of experimental parameters such as route of administration (primarily oral), dose ranges (commonly 100–500 mg/kg), and treatment duration (14–28 days), along with safety evaluation based on reported toxicity studies. Biochemical markers including oxidative stress indicators (MDA, SOD, CAT, GSH), inflammatory cytokines (IL-1β, IL-6, TNF-α), and cholinergic markers (AChE activity) were selected for assessment. Histopathological endpoints such as amyloid-beta plaque deposition, neuronal loss, and gliosis were incorporated using standard staining techniques, while behavioural tests including Morris's water maze, Y-maze, and novel object recognition were selected to evaluate cognitive function. These selections were based on literature-supported relevance and alignment with Alzheimer's disease mechanisms.

Section 2 (Prompts 21–40) focused on experimental design, validation, and optimization strategies for in vivo studies. AI-assisted prompts were used to design structured animal studies, including multi-group experimental setups with control, disease, and treatment groups using Moringa oleifera extracts at varying doses. Additional considerations included combination therapy approaches with standard drugs such as donepezil, evaluation of herb–drug interactions, and incorporation of recovery and reversibility study designs. Statistical analysis methods, including use of biological replicates, randomization, and ANOVA, were defined in accordance with OECD, ICMR, and ARRIVE guidelines to ensure reproducibility and ethical compliance. The entire workflow was systematically organized into structured datasets and experimental templates, providing a comprehensive and standardized methodology for evaluating the in vivo efficacy and safety of Moringa oleifera in Alzheimer's disease models.

### 2.7 Module 5: Clinical and Pv




**Figure 8:** clinical and PV Prompt Interface of Swalife MolecuNex AI for Alzheimer's Disease moringa Analysis.

this study was designed using an AI-assisted clinical and pharmacovigilance (PV) framework to evaluate the safety, efficacy, and translational potential of Moringa oleifera as an adjunct therapy in Alzheimer's disease. The Clinical & PV Design module was implemented as part of the structured AI research workflow, where standardized prompts were generated using the SwaLife AI Discovery & Study Design Studio and processed through computational models for systematic extraction of clinical data, trial design parameters, and safety monitoring strategies. Section 1 (Prompts 1–20) focused on collecting and interpreting public-domain clinical evidence, including standard-of-care treatments, existing preclinical and limited clinical studies on Moringa, and identification of key research gaps in neurodegenerative applications.

This phase also included the extraction of clinical trial design elements such as inclusion and exclusion criteria (e.g., mild cognitive impairment, early-stage Alzheimer's, biomarker-positive patients), commonly used endpoints (ADAS-Cog, CDR-SB, biomarkers like amyloid PET), and evaluation of herb–drug interactions with standard therapies such as donepezil and memantine. Pharmacovigilance-related data, including reported adverse drug reactions (ADRs), safety profiles, and WHO guidelines for herbal drug monitoring, were incorporated to ensure safety assessment. Additional parameters such as laboratory monitoring (CBC, LFTs), comorbid conditions (hypertension, diabetes), and real-world registry data (e.g., ALZ-NET) were also analyzed to support clinical applicability and long-term outcome tracking.

Section 2 (Prompts 21–40) focused on clinical study design, validation, and regulatory considerations for herbal add-on trials. AI-assisted prompts were used to design structured clinical protocols, including dose selection (e.g., 500–2000 mg/day standardized extract), treatment duration (6–12 months), and sample size estimation based on pilot study principles. Ethical and regulatory frameworks such as ICH-GCP, WHO, and AYUSH guidelines were integrated to ensure compliance, along with standardized herbal quality control measures (HPLC fingerprinting, microbial and heavy metal limits). Pharmacovigilance strategies included adverse event reporting, causality assessment, and integration into global safety databases. This comprehensive approach enabled systematic clinical planning, safety monitoring, and translational evaluation of Moringa oleifera as a potential multi-target adjunct therapy in Alzheimer's disease.

### 2.8 Module 6: Clinical and Pv




**Figure 9**: market IPR prompt Interface of Swalife MolecuNex AI for Alzheimer's Disease moringa Analysis.

this study was developed using an AI-assisted market analysis and intellectual property (IPR) evaluation framework to assess the translational and commercialization potential of Moringa oleifera in Alzheimer's disease. The Market & IPR module was implemented as part of the structured AI-driven workflow, where standardized prompts were generated using the SwaLife AI Discovery & Study Design Studio and processed through computational systems for systematic extraction of public-domain market data, patent landscapes, and regulatory insights. Section 1 (Prompts 1–20) focused on collecting and interpreting existing evidence on current Alzheimer's treatments, herbal product positioning, and gaps in standard-of-care guidelines, where conventional therapies such as cholinesterase inhibitors and memantine dominate, while herbal adjuncts remain underrepresented despite growing research interest.

This phase also included evaluation of preclinical and limited clinical evidence supporting Moringa oleifera, along with analysis of herbal usage trends, real-world data, and global market acceptance of plant-based therapies. Data related to clinical trial endpoints (ADAS-Cog, CDR-SB), inclusion criteria, and herb–drug interactions were assessed to understand feasibility of market translation. Additionally, pharmacovigilance data, adverse drug reaction patterns, and safety monitoring strategies were analyzed to determine risk profiles and regulatory considerations. The module further incorporated assessment of real-world registries (such as ALZ-NET) decentralized clinical trial trends, and prevalence of herbal medicine use, particularly in regions like India where acceptance of traditional medicine is high, supporting potential adoption pathways.

Section 2 (Prompts 21–40) focused on intellectual property mapping, commercialization strategy, and regulatory alignment for herbal drug development. AI-assisted prompts were used to identify patent opportunities related to extraction methods, formulation strategies, and novel drug delivery systems involving Moringa oleifera. Standardization requirements, including HPLC fingerprinting, quality control parameters, and WHO/AYUSH regulatory guidelines, were incorporated to ensure product consistency and compliance. Market feasibility analysis included evaluation of demand for neuroprotective nutraceuticals, competitive landscape, and scalability of plant-based therapeutics. The entire workflow enabled systematic identification of research gaps, patentable innovations, and commercialization pathways, providing a comprehensive methodology for translating Moringa oleifera from experimental research into a clinically and commercially viable therapeutic candidate for Alzheimer's disease.

## Result and discussion

### 3.1Module 1

Moringa oleifera showed strong multi-target activity in Alzheimer's disease, mainly regulating oxidative stress, neuroinflammation, and neuronal survival pathways. Key targets included NF-κB, Nrf2, AKT1, STAT3, TNF-α, IL-6, and IL-1β.[26]

Major phytochemicals (quercetin, kaempferol, glucomoringin, moringin, MIC-1) exhibited antioxidant and anti-inflammatory effects by reducing ROS and cytokine levels. Nrf2 activation and NF-κB inhibition were central

mechanisms. Preclinical studies reported improved cognition, reduced lipid peroxidation, increased antioxidant enzymes, lower amyloid-beta toxicity, and partial cholinergic restoration. Seed oil showed higher efficacy than leaf extracts. Safety was favorable, with effective doses of 100–250 mg/kg, but human dosage and pharmacokinetic data are lacking. Moringa oleifera acts mainly through indirect protective mechanisms rather than direct amyloid inhibition. Its effects are driven by reducing oxidative stress and inflammation.[27–29]

Its multi-target profile supports use in polyherbal or adjunct therapy. However, lack of standardization and reliance on animal studies limit clinical application. Further research is needed on standardization, human validation, BBB permeability, and clinical trials.[30,31]




**Figure 10**: Multi-panel histogram illustrating (A) pro-inflammatory mediator frequency, (B) mechanistic pathway distribution, (C) protein–protein interaction hub centrality, and (D) therapeutic target coverage in Moringa oleifera-based Alzheimer's disease research.

### 3.2 Module 2

This study evaluated the therapeutic potential of Moringa oleifera for Alzheimer's disease using phytochemical, computational, pharmacokinetic, and formulation approaches. Moringa oleifera contains over 110 bioactive compounds, mainly flavonoids (quercetin, kaempferol), along with terpenoids, alkaloids, and polysaccharides. The leaves showed the highest activity due to their rich polyphenol content.

Molecular docking revealed strong binding of key flavonoids to Alzheimer's targets such as AChE, BChE, and MAO. Compounds like quercetin and rutin showed high binding affinity (up to −10.6 kcal/mol), suggesting effective enzyme inhibition. These findings were supported by in vitro evidence of reduced oxidative stress and enzyme activity.[30]

ADMET analysis indicated favorable pharmacokinetics for major compounds (quercetin, kaempferol, chlorogenic acid, ellagic acid), including high absorption, low toxicity, and minimal Lipinski violations. Around 80–90% of compounds met drug-likeness criteria. Bioactivity-guided fractionation showed that ethyl acetate and ethanol extracts had the strongest antioxidant, anti-inflammatory, and metabolic effects due to enrichment of polyphenols. Nano formulations (SNEDDS, Nano emulsions, nanoparticles) improved solubility, stability, and bioavailability, with particle sizes below 150 nm enhancing absorption.

Toxicity studies confirmed safety at nutritional doses, though high doses (>2000 mg/kg) caused dose-dependent organ toxicity in animal models. The findings support Moringa oleifera as a multi-target therapeutic candidate for Alzheimer's disease. Flavonoids like quercetin and kaempferol act on multiple pathological pathways, including cholinesterase inhibition, oxidative stress, amyloid aggregation, and inflammation. Unlike single-target drugs

such as donepezil, Moringa compounds show multi-target-directed activity, aligning with modern neurodegenerative treatment strategies. Favorable ADMET profiles enhance their drug potential, although moderate blood–brain barrier permeability remains a limitation requiring advanced delivery systems. Fractionation results highlight the importance of extraction methods, with ethyl acetate fractions being most effective due to high polyphenol content. Nano-based delivery systems address poor solubility and significantly improve bioavailability, making them critical for clinical translation.[28,30,31]


**Figure 11:** Multi-panel histograms illustrating (A) Lipinski's rule compliance of major phytoconstituents, (B) bioactivity yield across solvent fractions, (C) frequency of toxicity evaluation studies, and (D) comparative distribution of native and derivative phytochemicals in Moringa oleifera-based Alzheimer's research.

### 3.3 Module3

Moringa oleifera shows significant neuroprotection in Alzheimer's in-vitro models, mainly in 2D SH-SY5Y systems. It reduces ROS, Aβ aggregation, and apoptosis, while improving mitochondrial function and cell viability. Its effects are driven by strong antioxidant activity (↑ SOD, CAT, GSH; ↓ MDA) and multi-pathway modulation, including reduced IL-6 and TNF-α, inhibition of NF-κB/COX-2, and regulation of apoptotic markers (↓ caspase-3, ↑ Bcl-2). It also targets AChE, BACE1, and Aβ aggregation[28,29,32]

Moringa acts as a multi-target addressing oxidative stress, inflammation, and apoptosis simultaneously. This makes it promising for Alzheimer's therapy. Future work should focus on advanced models, better validation methods, and combination therapies to improve clinical relevance

### 3.4 I Module 4

This AI-based study analyzed existing animal research on Moringa oleifera in Alzheimer's disease without conducting new experiments.

Moringa showed consistent neuroprotective effects across multiple models. It improved memory and learning, reduced oxidative stress and inflammation, lowered amyloid burden, and supported cholinergic function.It was generally safe, with effective doses between 100–500 mg/kg and low toxicity.

Moringa oleifera acts through multiple pathways, including antioxidant, anti-inflammatory, and anti-amyloid effects, making it a strong multi-target candidate for Alzheimer's.

However, results are based only on preclinical data. Differences across studies and the gap between animal models and human disease limit direct application. Clinical evidence is still lacking. Moringa oleifera shows promising neuroprotective potential in Alzheimer's disease, but human studies are needed to confirm its effectiveness.[30]

### 3.5 Module 5

AI-assisted analytical approach to synthesize clinical data, guidelines, and literature on Moringa oleifera in Alzheimer's disease (AD), without conducting new experiments. Current AD treatment relies on cholinesterase inhibitors and memantine, while Moringa is not included in standard guidelines.

AI-integrated data shows Moringa has neuroprotective effects (antioxidant, anti-inflammatory, anti-amyloid) in preclinical studies. However, human clinical evidence is very limited, with no large RCTs.Predicted herb–drug interactions are mild, and safety is generally favorable. High real-world use of herbal medicine supports its potential as an adjunct therapy, but clinical readiness remains moderate due to lack of strong evidence and standardization. The AI-assisted synthesis highlights a key gap between strong preclinical evidence and weak clinical validation. Moringa offers a multi-target therapeutic approach, unlike current treatments that are mainly symptomatic.AI enables integration of diverse datasets to identify patterns and gaps.reliance on secondary data, lack of standardization, and absence of clinical trials

### 3.6 Module 6

This study used an AI-assisted analytical approach to integrate public-domain clinical data, guidelines, and literature on Moringa oleifera in Alzheimer's disease (AD). The analysis shows that current AD treatment relies mainly on cholinesterase inhibitors and memantine, while Moringa is not part of standard clinical guidelines. However, AI-synthesized evidence highlights strong preclinical neuroprotective effects, including anti-amyloid, antioxidant, anti-inflammatory, and anti-acetylcholinesterase activity. human clinical evidence is extremely limited, with no large, randomized trials in AD patients. Safety data suggest Moringa is generally well tolerated, with mild side effects and minor herb–drug interactions. Real-world data show high herbal medicine use, especially in India, supporting feasibility as an adjunct therapy. However, overall clinical readiness is moderate, mainly due to lack of standardization and absence of strong efficacy data. The AI-assisted synthesis clearly reveals a gap between promising preclinical findings and limited clinical translation. While current AD therapies are largely symptomatic, Moringa offers a multi-target therapeutic approach, addressing oxidative stress, inflammation, and amyloid pathology simultaneously. This aligns with emerging strategies for complex diseases like Alzheimer's. [33]

limitations include reliance on secondary data, variability in plant composition, and lack of standardized formulations and clinical trials. Moringa appears suitable as an adjunct therapy alongside standard treatment, rather than a replacement. Overall, the findings emphasize that while Moringa has strong potential, well-designed clinical trials and better standardization are essential for its integration into clinical practice.[32]

## Conclusion

This study demonstrates that Moringa oleifera holds strong potential as a multi-target therapeutic candidate for Alzheimer's disease, primarily due to its ability to modulate oxidative stress, neuroinflammation, cholinergic dysfunction, and amyloid-related pathways. The integration of AI-assisted drug discovery approaches enabled efficient synthesis of complex datasets, highlighting consistent neuroprotective effects across computational, in vitro, and in vivo studies.

Unlike conventional single-target drugs, Moringa oleifera aligns with emerging treatment strategies that address the multifactorial nature of neurodegenerative diseases. Its favorable safety profile, combined with broad pharmacological activity, supports its potential role as an adjunct therapy rather than a standalone treatment. However, the current evidence is largely preclinical, and significant gaps remain in clinical validation, pharmacokinetics, and formulation standardization.

Overall, while Moringa oleifera represents a promising phytotherapeutic approach, its translation into clinical practice will depend on rigorous human studies, standardized preparations, and regulatory validation.

**Future Directions**

Future research should focus on bridging the gap between strong preclinical evidence and limited clinical application of Moringa oleifera in Alzheimer's disease through a multi-dimensional and translational approach. Well-designed randomized controlled trials are required to establish clinical efficacy, determine optimal dosing, and evaluate long-term safety in human populations. Simultaneously, standardization of extracts with well-defined phytochemical profiles is essential to ensure consistency, reproducibility, and regulatory acceptance. Further investigations into pharmacokinetics, including absorption, distribution, metabolism, excretion, and especially blood–brain barrier permeability, are necessary to better understand its therapeutic potential in central nervous system disorders. Advanced drug delivery systems such as nanoparticles and self-nanoemulsifying drug delivery systems (SNEDDS) should be explored to enhance bioavailability and enable targeted brain delivery.

In addition, mechanistic studies using network pharmacology and multi-omics approaches are needed to elucidate the complex molecular pathways and synergistic interactions of Moringa bioactives. Evaluation of combination and adjunct therapies with existing Alzheimer's drugs may provide insights into additive or synergistic therapeutic effects. From a translational perspective, establishing clear regulatory frameworks and integrating AI-assisted methodologies will be critical for scalable and reproducible phytopharmaceutical development. Furthermore, incorporation of real-world evidence and pharmacovigilance systems is essential to monitor long-term safety, herb–drug interactions, and population-level outcomes, thereby supporting the safe and effective clinical integration of Moringa oleifera in Alzheimer's disease management.

## 1. References


1. Dey, M., & Amour, A. (2025). Applications of artificial intelligence in drug discovery. *Emerging Topics in Life Sciences*, *8*(2), 107–109. https://doi.org/10.1042/ETLS20250001

2. Malheiro, V., Santos, B., Figueiras, A., & Mascarenhas-Melo, F. (2025). The Potential of Artificial Intelligence in Pharmaceutical Innovation: From Drug Discovery to Clinical Trials. *Pharmaceuticals 2025, Vol. 18, Page 788*, *18*(6), 788. https://doi.org/10.3390/ph18060788

3. Vidiyala, N., Sunkishala, P., Parupathi, P., & Nyavanandi, D. (2025). The Role of Artificial Intelligence in Drug Discovery and Pharmaceutical Development: A Paradigm Shift in the History of Pharmaceutical Industries. *AAPS PharmSciTech 2025 26:5*, *26*(5), 133-. https://doi.org/10.1208/s12249-025-03134-3

4. Kumar, P., Chaudhary, B., Arya, P., Chauhan, R., Devi, S., Parejiya, P. B., & Gupta, M. M. (2025). Advanced Artificial Intelligence Technologies Transforming Contemporary Pharmaceutical Research. *Bioengineering 2025, Vol. 12, Page 363*, *12*(4), 363. https://doi.org/10.3390/bioengineering12040363

5. Wang, H., Fu, T., Du, Y., Gao, W., Huang, K., Liu, Z., Chandak, P., Liu, S., Van Katwyk, P., Deac, A., Anandkumar, A., Bergen, K., Gomes, C. P., Ho, S., Kohli, P., Lasenby, J., Leskovec, J., Liu, T. Y., Manrai, A., … Zitnik, M. (2023). Scientific discovery in the age of artificial intelligence. *Nature*, *620*(7972), 47–60. https://doi.org/10.1038/s41586-023-06221-2

6. Wang, H., Fu, T., Du, Y., Gao, W., Huang, K., Liu, Z., Chandak, P., Liu, S., Van Katwyk, P., Deac, A., Anandkumar, A., Bergen, K., Gomes, C. P., Ho, S., Kohli, P., Lasenby, J., Leskovec, J., Liu, T. Y., Manrai, A., … Zitnik, M. (2023). Publisher Correction: Scientific discovery in the age of artificial intelligence (Nature, (2023), 620, 7972, (47-60), 10.1038/s41586-023-06221-2). *Nature*, *621*(7978), E33. https://doi.org/10.1038/s41586-023-06559-7

7. White, J., Fu, Q., Hays, S., Sandborn, M., Olea, C., Gilbert, H., Elnashar, A., Spencer-Smith, J., & Schmidt, D. C. (2023). *A Prompt Pattern Catalog to Enhance Prompt Engineering with ChatGPT*. http://arxiv.org/abs/2302.11382

8. Gu, Z., Yan, Y., Liu, H., Wu, D., Yao, H., Lin, K., & Li, X. (2024). Discovery of Covalent Lead Compounds Targeting 3CL Protease with a Lateral Interactions Spiking Neural Network. *Journal of Chemical Information and Modeling*, *64*(8), 3047–3058. https://doi.org/10.1021/acs.jcim.3c01900

9. Schilling-Wilhelmi, M., Ríos-García, M., Shabih, S., Gil, M. V., Miret, S., Koch, C. T., Márquez, J. A., & Jablonka, K. M. (2025). From text to insight: large language models for chemical data extraction. *Chemical Society Reviews*, *54*(3), 1125–1150. https://doi.org/10.1039/d4cs00913d

10. Ramos, M. C., Collison, C. J., & White, A. D. (2025). A review of large language models and autonomous agents in chemistry. *Chemical Science*, *16*(6), 2514–2572. https://doi.org/10.1039/d4sc03921a

11. Info, A., & Mitchell, M. (2024). □ *DEBATES ON THE NATURE OF ARTIFICIAL GENERAL INTELLIGENCE Debates on the nature of articial general intelligence*. *383*(6689). https://doi.org/10.1126/science.ado7069

12. Safiri, S., Ghaffari Jolfayi, A., Fazlollahi, A., Morsali, S., Sarkesh, A., Daei Sorkhabi, A., Golabi, B., Aletaha, R., Motlagh Asghari, K., Hamidi, S., Mousavi, S. E., Jamalkhani, S., Karamzad, N., Shamekh, A., Mohammadinasab, R., Sullman, M. J. M., Şahin, F., & Kolahi, A. A. (2024). Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges. *Frontiers in Medicine*, *11*. https://doi.org/10.3389/fmed.2024.1474043

13. Soni, U., Singh, K., Jain, D., & Pujari, R. (2025). Exploring Alzheimer's disease treatment: Established therapies and novel strategies for future care. *European Journal of Pharmacology*, *998*. https://doi.org/10.1016/j.ejphar.2025.177520

14. Sinha, S., Wal, P., Goudanavar, P., Divya, S., Kimothi, V., Jyothi, D., Sharma, M. C., & Wal, A. (2024). Research on Alzheimer's Disease (AD) Involving the Use of In vivo and In vitro Models and Mechanisms. *Central Nervous System Agents in Medicinal Chemistry*, *25*(2), 123–142. https://doi.org/10.2174/0118715249293642240522054929

15. Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2024). Alzheimer's Disease: Exploring the Landscape of Cognitive Decline. *ACS Chemical Neuroscience*, *15*(21), 3800–3827. https://doi.org/10.1021/acschemneuro.4c00339

16. Manoharan, S., Essa, M. M., Vinoth, A., Kowsalya, R., Manimaran, A., & Selvasundaram, R. (2016). Alzheimer's Disease and Medicinal Plants: An Overview. *Advances in Neurobiology*, *12*, 95–105. https://doi.org/10.1007/978-3-319-28383-8_6

17. Mundkar, M., Bijalwan, A., Soni, D., & Kumar, P. (2022). Neuroprotective potential of Moringa oleifera mediated by NF-kB/Nrf2/HO-1 signaling pathway: A review. *Journal of Food Biochemistry*, *46*(12). https://doi.org/10.1111/jfbc.14451

18. Rojas-Silva, P., Tumer, T. B., Kuhn, P., Richard, A. J., Wicks, S., Stephens, J. M., Wang, Z., Mynatt, R., Cefalu, W., & Raskin, I. (2015). Isothiocyanate-rich Moringa oleifera extract reduces weight gain, insulin resistance, and hepatic gluconeogenesis in mice. *Molecular Nutrition & Food Research*, *59*(6), 1013–1024. https://doi.org/10.1002/mnfr.201400679

19. Azlan, U. K., Khairul Annuar, N. A., Mediani, A., Aizat, W. M., Damanhuri, H. A., Tong, X., Yanagisawa, D., Tooyama, I., Wan Ngah, W. Z., Jantan, I., & Hamezah, H. S. (2022). An insight into the neuroprotective and anti-neuroinflammatory effects and mechanisms of Moringa oleifera. *Frontiers in Pharmacology*, *13*, 1035220. https://doi.org/10.3389/fphar.2022.1035220

20. Ghimire, S., Subedi, L., Acharya, N., & Gaire, B. P. (2021). Moringa oleifera: A Tree of Life as a Promising Medicinal Plant for Neurodegenerative Diseases. *Journal of Agricultural and Food Chemistry*, *69*(48), 14358–14371. https://doi.org/10.1021/acs.jafc.1c04581

21. Singhal, K., Azizi, S., Tu, T., Mahdavi, S. S., Wei, J., Chung, H. W., Scales, N., Tanwani, A., Cole-Lewis, H., Pfohl, S., Payne, P., Seneviratne, M., Gamble, P., Kelly, C., Babiker, A., Schärli, N.,

Chowdhery, A., Mansfield, P., Demner-Fushman, D., … Natarajan, V. (2023). Large language models encode clinical knowledge. *Nature*, *620*(7972), 172–180. https://doi.org/10.1038/s41586-023-06291-2

22. Dara, S., Dhamercherla, S., Jadav, S. S., Babu, C. M., & Ahsan, M. J. (2022). Machine Learning in Drug Discovery: A Review. *Artificial Intelligence Review*, *55*(3), 1947–1999. https://doi.org/10.1007/s10462-021-10058-4

23. Zhang, Y., Khan, S. A., Mahmud, A., Yang, H., Lavin, A., Levin, M., Frey, J., Dunnmon, J., Evans, J., Bundy, A., Dzeroski, S., Tegner, J., & Zenil, H. (2025). Exploring the role of large language models in the scientific method: from hypothesis to discovery. *Npj Artificial Intelligence 2025 1:1*, *1*(1), 14-. https://doi.org/10.1038/s44387-025-00019-5

24. *Perplexity AI Explained: LLMs, Functionality, And Comparisons*. (n.d.). Retrieved March 21, 2026, from https://alidropship.com/dropshipping-wiki/perplexity/?utm_source=chatgpt.com

25. *Perplexity AI Copilot underlying model*. (n.d.). Retrieved March 21, 2026, from https://seabuckdigital.com/perplexity-ai-copilot-underlying-model/?utm_source=chatgpt.com

26. Wang, J. Z., Wang, Z. H., & Tian, Q. (2014). Tau hyperphosphorylation induces apoptotic escape and triggers neurodegeneration in Alzheimer's disease. *Neuroscience Bulletin*, *30*(2), 359–366. https://doi.org/10.1007/s12264-013-1415-y

27. Khan, R. M., & Khan, R. M. (2025). Moringa oleifera extract inactivates nuclear transcription factor nuclear factor-kappa B p65/50 subunits and inhibits expression of tumor necrosis factor-α, interleukin-6, and interleukin-8 in phorbol 12-myristate 13-acetate-stimulated human breast cance…. *International Journal of Health Sciences*, *19*(6), 1–10. https://doi.org/10.25259/ijhs_8871

28. Irlia Sofea Mohammad Zamani, N., Azura Jam, F., Jia Yi, L., Wan Yi, C., Rajendran, T., Willie Wong, P., Tang Yee Ying, A., Kalthum Azlan, U., Shahirah Hamezah, H., Mediani, A., & Rosseleena Rohani, E. (2025). *The Open Medicinal Chemistry Journal Advancing Alzheimer's Therapy with Moringa oleifera: Bioactive Insights, Mechanistic Pathways, and Strategies for Efficacy and Standardization*. *19*, 18741045371837. https://doi.org/10.2174/0118741045371837250212060043

29. Manogna, C., & Margesan, T. (2024). In silico and pharmacokinetic studies of glucomoringin from Moringa oleifera root for Alzheimer's disease like pathology. *Future Science OA*, *10*(1). https://doi.org/10.2144/fsoa-2023-0255

30. Ahmad, J., Khan, I., & Blundell, R. (2019). Moringa oleifera and glycemic control: A review of current evidence and possible mechanisms. *Phytotherapy Research*, *33*(11), 2841–2848. https://doi.org/10.1002/ptr.6473

31. da Silva Parente, T. S. J., Sarandy, M. M., de Araújo, E. R. D., Gonçalves, R. V., & Zucolotto, S. M. (2025). Effect of Moringa oleifera on inflammatory diseases: an umbrella review of 26 systematic reviews. *Frontiers in Pharmacology*, *16*, 1572337. https://doi.org/10.3389/fphar.2025.1572337

32. Mahaman, Y. A. R., Huang, F., Wu, M., Wang, Y., Wei, Z., Bao, J., Salissou, M. T. M., Ke, D., Wang, Q., Liu, R., Wang, J. Z., Zhang, B., Chen, D., & Wang, X. (2018). Moringa Oleifera Alleviates Homocysteine-Induced Alzheimer's Disease-Like Pathology and Cognitive Impairments. *Journal of Alzheimer's Disease*, *63*(3), 1141. https://doi.org/10.3233/JAD-180091

33. Shakira, & Maulina, M. (2025). Exploration of Moringa Oleifera and Curcuma Longa Compounds as Multi-Target Agents for Alzheimer's Disease Through Bioinformatics Analysis. *SCRIPTA SCORE Scientific Medical Journal*, *7*(1), 26–35. https://doi.org/10.32734/scripta.v7i1.21326